Roswell Park’s Cuban Collaboration
Through an historic partnership with Cuba’s Centro de Inmunología Molecular, or CIM, Roswell Park is helping to develop several innovative and potentially life-saving cancer therapies. The first of these new approaches to be available to U.S. patients is CIMAvax-EGF®, an immunotherapy for lung cancer. We are the only facility in the country that offers this groundbreaking treatment.
Additional Clinical Trials
NCI-supported clinical trials are offered at locations across the United States and Canada for both common and rare cancers. If you aren’t eligible for the CIMAvax clinical trial, there may be a clinical trial better suited to your type of cancer.
Frequently Asked Questions
CIMAvax-EGF is a lung cancer treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Our trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced non-small cell lung cancer (NSCLC).
Developed by researchers at the Center for Molecular Immunology (CIM) in Havana, Cuba, CIMAvax-EGF blocks a type of protein — epidermal growth factor (EGF) — that cancer cells need to grow. It does not kill cells directly, cancerous cells or otherwise, but “starves” them by preventing EGF from attaching to its proper receptor (EGFR) on the cell. This connection is required for the cell to grow and proliferate. Without it, the cancer cell does not multiply, and dies. CIMAvax blocks EGF by manipulating the patient’s immune response.
A “carrier protein” in CIMAvax triggers the immune system to produce antibodies against the EGF protein to neutralize it. This depletes circulating EGF from the blood, depriving the cancer cells of this important key to growth and survival.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tumor stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
This trial will enroll up to 175 patients with either:
- Advanced (Stage IIIB/IV) non-small cell lung cancer (NSCLC) whose tumors express PD-L1 and who have not received prior immunotherapy or
- Advanced recurrent head and neck squamous cell carcinoma (HNSCC)
In addition to CIMAvax-EGF, patients will also receive the FDA-approved dose of nivolumab, for HNSCC, or pembrolizumab, for NSCLC.
Inclusion criteria include (but are not limited to):
- Adults with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) or advanced recurrent head and neck squamous cell carcinoma (HNSCC)
- NSCLC patients eligible only if their tumors express PD-L1
- Must be eligible for treatment with nivolumab or pembrolizumab as standard of care
- Have a life expectancy of at least 6 months
- Have a patient performance status (ECOG) of ≤ 1 (patient is ambulatory; capable of all self-care, but unable to carry out any work activities; up and about more than 50% of waking hours)
Exclusion criteria include (but are not limited to):
- Previously treated with immunotherapy for their cancer
- Recent treatment with investigational agents
- Presence of a genetic/tumor mutation that has not been treated with an approved targeted therapy
- Use of immunosuppressant drugs (steroids, azathioprine, tacrolimus, cyclosporine, etc.) in last month
- Currently receiving or has received systemic corticosteroids within 4 weeks of beginning study drug, or has not recovered fully from side effects of such treatment.
- Major surgery within last 14 days, or has not recovered from major side effects of prior surgery (tumor biopsy not considered major surgery)
- Known immunosuppressive or autoimmune disease, active cardiac disease, history of cardiac dysfunction, clinically serious infection, or other serious uncontrolled medical conditions
- History of myocarditis
- Pregnant or nursing
CIMAvax is currently available in the U.S. only to eligible patients accepted into Roswell Park’s clinical trial, which requires being in Buffalo, NY, for an extended period of time. Roswell Park is the only U.S. institution with clearance from the U.S. Food and Drug Administration (FDA) to conduct clinical trials with this immunotherapy. CIMAvax-EGF Clinical Trial: Find out if you’re eligible
Roswell Park has no information on the specifics or advisability of receiving CIMAvax outside of the U.S. The travel of all U.S. citizens to Cuba is strictly regulated by laws pertaining to the Embargo, and anyone planning travel to Cuba needs to first check these restrictions. U.S. health insurance is very unlikely to cover CIMAvax obtained in a foreign country.
Different insurance companies have different policies for covering care delivered as part of a clinical trial. CIMAvax will be provided free of charge by the CIM. Nivolumab is FDA-approved for treatment in this group of lung cancer patients, so that is standard of care, and billed to insurance.
Expanded access, sometimes called compassionate use, is the use outside of a clinical trial of an investigational medical product (i.e., one that has not been approved by FDA). No, we do not have a mechanism for Roswell Park to offer it as compassionate use.
In order to bring CIMAvax to patients as quickly as possible, the Roswell Park Alliance Foundation is proud to commit $4 million in donor dollars to cover the cost of the initial clinical trials. These funds are raised through individual donations to Roswell Park and community fundraising events, including the foundation’s Ride For Roswell and Goin’ Bald For Bucks program. Learn how you can join the Alliance Foundation in supporting this effort.
Find out if you are eligible for the CIMAvax clinical trial.
Help us bring the vaccine to lung cancer patients as quickly as possible.